Earnings summaries and quarterly performance for Kiniksa Pharmaceuticals International.
Executive leadership at Kiniksa Pharmaceuticals International.
Sanj K. Patel
Detailed
Chief Executive Officer
CEO
ET
Eben Tessari
Detailed
Executive Vice President and Chief Operating Officer
JF
John F. Paolini
Detailed
Executive Vice President and Chief Medical Officer
MR
Mark Ragosa
Detailed
Senior Vice President and Chief Financial Officer
MM
Michael Megna
Detailed
Chief Accounting Officer
RM
Ross Moat
Detailed
Executive Vice President and Chief Commercial Officer
Board of directors at Kiniksa Pharmaceuticals International.
BD
Barry D. Quart
Detailed
Director
FJ
Felix J. Baker
Detailed
Lead Independent Director
GB
G. Bradley Cole
Detailed
Director
KJ
Kimberly J. Popovits
Detailed
Director
MC
M. Cantey Boyd
Detailed
Director
RS
Richard S. Levy
Detailed
Director
SR
Stephen R. Biggar
Detailed
Director
TR
Thomas R. Malley
Detailed
Director
TL
Tracey L. McCain
Detailed
Director
Research analysts who have asked questions during Kiniksa Pharmaceuticals International earnings calls.
AR
Anupam Rama
JPMorgan Chase & Co.
5 questions for KNSA
Also covers: APLS, BBIO, BOLD +16 more
Eva Fortea-Verdejo
Wells Fargo Securities
5 questions for KNSA
Also covers: EXEL, KYMR, RCUS
David Nierengarten
Wedbush Securities
4 questions for KNSA
Also covers: ARGX, ITOS, NUVB +4 more
PC
Paul Choi
Goldman Sachs
3 questions for KNSA
Also covers: AMRN, ARVN, ASND +12 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for KNSA
Also covers: ACRS, CRVS, CTMX +12 more
RS
Roger Song
Jefferies
2 questions for KNSA
Also covers: AADI, AKBA, ALT +13 more
Geoff Meacham
Citigroup Inc.
1 question for KNSA
Also covers: ABBV, AMGN, BMY +8 more
KC
Kyuwon Choi
Goldman Sachs
1 question for KNSA
Also covers: AMRN, ASND, BHVN +9 more
Liisa Bayko
Evercore ISI
1 question for KNSA
Also covers: ALT, BCRX, INSM +7 more
MK
Mary Kate
Citigroup Inc.
1 question for KNSA
NL
Nick Larissa
TD Cowen
1 question for KNSA
Recent press releases and 8-K filings for KNSA.
Kiniksa Pharmaceuticals Provides Corporate Update and 2026 ARCALYST Revenue Guidance
KNSA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals reported unaudited ARCALYST net product revenue of $677.5 million for the full year 2025, marking approximately 62% year-over-year growth from $417.0 million in 2024.
- The company projects 2026 ARCALYST net product revenue to be between $900 million and $920 million.
- As of December 31, 2025, Kiniksa held an unaudited cash, cash equivalents, and short-term investments balance of $414.1 million, with no debt.
- Kiniksa expects KPL-387 Phase 2 recurrent pericarditis data in the second half of 2026 and plans to initiate a KPL-1161 Phase 1 trial by the end of 2026.
2 days ago
Kiniksa Reports Strong ARCALYST Revenue and Provides 2026 Guidance
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa reported full year 2025 unaudited net revenue of $677.5 million for ARCALYST, representing 62% year-over-year growth, and issued 2026 net product revenue guidance of $900-$920 million.
- ARCALYST has generated around $1.5 billion in cumulative net revenue since its launch and is being positioned as the second-line standard of care for recurrent pericarditis, supported by new ACC clinical guidance.
- The company is advancing KPL-387 in a Phase 2/3 study for recurrent pericarditis, with dose-focusing data expected in the second half of 2026 and a commercialization target of 2028-2029.
- Kiniksa also plans for KPL-1161 to enter the clinic by the end of 2026 and reported around $414 million in year-end cash reserves.
2 days ago
Kiniksa Updates on ARCALYST Performance and Pipeline Progress
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa reported full year 2025 unaudited net revenue of $677.5 million for ARCALYST, representing 62% year-over-year growth, and provided 2026 net product revenue guidance of $900-$920 million.
- The company is advancing its clinical portfolio, with KPL-387 in a phase 2/3 study for recurrent pericarditis, expecting dose-focusing data in the second half of 2026, and KPL-1161 anticipated to enter the clinic by the end of 2026.
- Commercialization efforts for ARCALYST are focused on establishing it as the second-line standard of care for recurrent pericarditis, with 18% penetration into the multiple recurrent patient group by the end of 2025, up from 13% at the end of 2024.
- Kiniksa ended the year with approximately $414 million in cash reserves and saw 325 additional new ARCALYST prescribers in Q4 2025, bringing the total to over 4,150 prescribers.
2 days ago
Kiniksa Reports Strong 2025 ARCALYST Revenue and Provides 2026 Guidance
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa announced full year 2025 unaudited net revenue for ARCALYST of $677.5 million, representing 62% year-over-year growth, and issued full year 2026 net product revenue guidance of $900-$920 million.
- ARCALYST has generated approximately $1.5 billion in cumulative net revenue since its launch, and Kiniksa ended 2025 with around $414 million in cash reserves.
- The company is advancing its pipeline, with KPL-387 in a Phase 2/3 study for recurrent pericarditis, expecting data from the dose-focusing portion in the second half of 2026 and targeting commercialization in 2028-2029.
- Kiniksa also plans for KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, to enter the clinic by the end of 2026.
2 days ago
Kiniksa Reports Strong ARCALYST Performance and Advances Clinical Pipeline
KNSA
Guidance Update
New Projects/Investments
Earnings
- Kiniksa (KNSA) projects ARCALYST revenue of $900M to $920M for 2026 and reported $180.9M in product revenue for Q3 2025, contributing to $18.4M in net income for the quarter.
- The company maintained a strong financial position with approximately $414M in cash reserves at the end of 2025 and anticipates remaining cash flow positive on an annual basis.
- ARCALYST has achieved ~$1.5B in net revenue since launch and has become the ACC-recommended second-line treatment for recurrent pericarditis, with its use increasing to 71% in 2023.
- Kiniksa is advancing its clinical pipeline, with KPL-387 in a Phase 2/3 trial for recurrent pericarditis, expecting Phase 2 data in 2H 2026, and KPL-1161 initiating a Phase 1 trial by the end of 2026.
3 days ago
Kiniksa Reports Strong Q3 2025 Revenue, Raises Full-Year Guidance, and Provides Pipeline Update
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa reported $180.9 million in net product revenue for Q3 2025, representing a 61% year-over-year increase. The company also increased its net revenue guidance for full year 2025 to between $670 million and $675 million.
- ARCALYST has generated over $1 billion in net product revenue since its FDA approval 4.5 years ago and has a 15% penetration rate in the multiple recurrence population.
- The company's pipeline asset, KPL-387, received Orphan Drug Designation in October and is undergoing a Phase 2/3 development program, with the Phase 2 dose-focusing portion expected to read out in the second half of 2026.
- Kiniksa reported $352 million in cash reserves at the time of its Q3 earnings.
Nov 17, 2025, 2:30 PM
Kiniksa Updates on ARCALYST Revenue Guidance and KPL-387 Development
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa reported Q3 net product revenue for ARCALYST of $180.9 million, representing a 61% year-over-year increase compared to Q3 2024. The company also increased its full-year 2025 net revenue guidance to between $670 million and $675 million.
- Since its FDA approval approximately four and a half years ago, ARCALYST has delivered over $1 billion in net product revenue. The drug has achieved 15% penetration into the multiple recurrence population, and 20% of patients are now prescribed ARCALYST for their first recurrence, an increase from 15% a year ago.
- The company's pipeline asset, KPL-387, received Orphan Drug Designation from the FDA in October for recurrent pericarditis. Phase 2 dose-focusing data from its Phase 2/3 development program is expected to read out in the second half of 2026.
- Kiniksa maintains a strong financial position, reporting over $350 million in cash reserves at its Q3 earnings call.
Nov 17, 2025, 2:30 PM
Kiniksa Provides Business Update and Increased 2025 Revenue Guidance
KNSA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Kiniksa increased its net revenue guidance for full year 2025 to between $670 million and $675 million and reported over $350 million in cash reserves at Q3 earnings.
- The company's commercial product, ARCALYST, has generated over $1 billion in net product revenue since its FDA approval 4.5 years ago, with Q3 net product revenue reaching $180.9 million, a 61% year-over-year increase.
- ARCALYST has achieved 15% penetration in the multiple recurrence population and is seeing increased adoption in first recurrence patients, now representing 20% of prescriptions.
- Kiniksa is advancing its clinical pipeline, with KPL-387 for recurrent pericarditis receiving Orphan Drug Designation and its Phase II dose-focusing data expected in H2 2026. This monthly auto-injector is highly anticipated by patients and healthcare professionals.
Nov 17, 2025, 2:30 PM
Kiniksa Pharmaceuticals announces Q3 2025 results and raises full-year guidance
KNSA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals reported Q3 2025 ARCALYST revenue of $180.9 million, representing approximately 61% year-over-year growth.
- The company raised its full-year 2025 net revenue guidance to between $670 million and $675 million from its previous guidance of $625 million and $640 million.
- Net income for Q3 2025 was $18.4 million.
- Kiniksa maintains a strong financial position with approximately $352.1 million in cash, cash equivalents, and short-term investments as of September 30, 2025, and expects its operating plan to remain cash flow positive on an annual basis.
- KPL-387 received US Orphan Drug Designation for pericarditis, with Phase 2 data anticipated in the second half of 2026.
Oct 28, 2025, 12:30 PM
Kiniksa Pharmaceuticals Reports Strong Q3 2025 Results and Raises Full-Year ARCALYST Sales Guidance
KNSA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Kiniksa Pharmaceuticals reported Q3 2025 ARCALYST revenue of $180.9 million, marking a 61% year-over-year increase, and achieved a net income of $18.4 million for the quarter, compared to a net loss in the prior year.
- The company raised its full-year 2025 ARCALYST net sales guidance to between $670 million and $675 million, an increase from its previous guidance of $625 million to $640 million.
- Key drivers for ARCALYST's growth included the highest quarterly new patient enrollments since launch, an increase of over 350 new prescribers in Q3, and an average duration of therapy that extended to approximately 32 months.
- KPL-387, Kiniksa's development program, received FDA orphan drug designation for pericarditis (including recurrent pericarditis) and is expected to report Phase 2 dose-focusing data in the second half of 2026.
Oct 28, 2025, 12:30 PM
Quarterly earnings call transcripts for Kiniksa Pharmaceuticals International.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more